Nasus Pharma Ltd. announced the closing of a private placement, raising $15.0 million in gross proceeds. The company plans to use the funds to advance its intranasal epinephrine product candidate and expand its pipeline of innovative products. The securities sold in the private placement include ordinary shares and warrants at a premium price. The warrants have an exercise price of $6.53 per share and will expire in two years. Nasus Pharma aims to use the funds for clinical development, first-in-human studies, and general corporate purposes. The company plans to file a registration statement with the SEC for the securities issued in the private placement.

Read more at GlobeNewswire: Nasus Pharma Announces Closing of $15.0 Million Private